Tarsus Pharmaceuticals, Inc. Common Stock (TARS)
Health Care – BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 370
- Market Cap
- $2.9B
About Tarsus Pharmaceuticals, Inc. Common Stock
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.